BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1012@pharmaconomics
DTSTAMP:20260707T033826Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:NGNE Phase 2 — NGN-401
DESCRIPTION:Phase 2 trial results for NGN-401 in Rett Syndrome are due Jun 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000012/ngne_4qye25earningsrelease.htm\n\nTrack it: https://pharmaconomics.com/e/1012
URL:https://pharmaconomics.com/e/1012
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:NGNE catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR